Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Receivables - Other (2016 - 2024)

Historic Receivables - Other for Tg Therapeutics (TGTX) over the last 5 years, with Q4 2024 value amounting to $23.5 million.

  • Tg Therapeutics' Receivables - Other rose 29830.51% to $23.5 million in Q4 2024 from the same period last year, while for Dec 2024 it was $23.5 million, marking a year-over-year increase of 29830.51%. This contributed to the annual value of $23.5 million for FY2024, which is 29830.51% up from last year.
  • Per Tg Therapeutics' latest filing, its Receivables - Other stood at $23.5 million for Q4 2024, which was up 29830.51% from $6.5 million recorded in Q1 2024.
  • In the past 5 years, Tg Therapeutics' Receivables - Other ranged from a high of $23.5 million in Q4 2024 and a low of $5.9 million during Q4 2023